Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 459

1.

Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units.

Arenas MD, Alvarez-Ude F, Gil MT, Soriano A, Egea JJ, Millán I, Amoedo ML, Muray S, Carretón MA.

Nephrol Dial Transplant. 2006 Jun;21(6):1663-8. Epub 2006 Feb 7.

PMID:
16464885
2.

K/DOQI guideline requirements for calcium, phosphate, calcium phosphate product, and parathyroid hormone control in dialysis patients: can we achieve them?

Wei M, Taskapan H, Esbaei K, Jassal SV, Bargman JM, Oreopoulos DG.

Int Urol Nephrol. 2006;38(3-4):739-43. Epub 2006 Dec 11.

PMID:
17160632
3.

Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia.

Maduell F, Gorriz JL, Pallardo LM, Pons R, Santiago C; Multicentric group for the study of the phosphocalcic metabolism in the community of Valencia..

J Nephrol. 2005 Nov-Dec;18(6):739-48.

PMID:
16358233
4.

Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.

Arenas MD, Alvarez-Ude F, Gil MT, Moledous A, Malek T, Nuñez C, Devesa R, Carretón MA, Soriano A.

Nephrol Dial Transplant. 2007 Jun;22(6):1639-44. Epub 2007 Feb 3.

PMID:
17277339
5.

Adherence to K/DOQI guidelines for calcium-based phosphate binders in clinical practice.

Shastri J, Tran A, Covit A, Pepe J, Sherman RA.

J Ren Nutr. 2008 Jul;18(4):370-4. doi: 10.1053/j.jrn.2008.04.011.

PMID:
18558302
6.

Are CSN and NKF-K/DOQI mineral metabolism guidelines for hemodialysis patients achievable? Results from a provincial renal program.

Wazny LD, Raymond CB, Lesperance EM, Bernstein KN.

CANNT J. 2008 Apr-Jun;18(2):36-41, 44-50; quiz 42-3, 51-2. English, French.

PMID:
18669010
7.

[CA-P control in haemodialysis and K/DOQI guidelines].

Rivera F, Sánchez de la Nieta MD, Echarri R, Anaya S, Carreño A, Vozmediano MC, Alcaide MP.

Nefrologia. 2006;26(3):351-7. Spanish.

9.

Marked improvement in bone metabolism parameters after increasing the dialysate calcium concentration from 2.5 to 3 mEq/L in nonhypercalcemic hemodialysis patients.

Molina Vila P, Sánchez Pérez P, Garrigós Almerich E, Peris Domingo A.

Hemodial Int. 2008 Jan;12(1):73-9. doi: 10.1111/j.1542-4758.2008.00244.x.

PMID:
18271845
10.

Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges.

Craver L, Marco MP, Martínez I, Rue M, Borràs M, Martín ML, Sarró F, Valdivielso JM, Fernández E.

Nephrol Dial Transplant. 2007 Apr;22(4):1171-6. Epub 2007 Jan 5.

PMID:
17205962
11.

Consequences of the implementation of K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease in a population of patients on chronic hemodialysis.

Arenas MD, Alvarez-Ude F, Torregrosa V, Gil MT, Carretón MA, Moledous A, Nuñez C, Devesa R, Albiach B.

J Nephrol. 2007 Jul-Aug;20(4):453-61.

PMID:
17879212
12.

Adherence to K/DOQI practice guidelines for bone metabolism and disease.

Hoy T, Fisher M, Barber B, Borker R, Stolshek B, Goodman W.

Am J Manag Care. 2007 Nov;13(11):620-5.

13.

K/DOQI guidelines for bone metabolism and disease in chronic kidney disease patients: some therapeutic implications.

Uribarri J; National Kidney Foundation..

Semin Dial. 2004 Sep-Oct;17(5):349-50.

PMID:
15461740
14.

Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: a cross-sectional multicentre study.

Lorenzo V, Martin-Malo A, Perez-Garcia R, Torregrosa JV, Vega N, de Francisco AL, Cases A.

Nephrol Dial Transplant. 2006 Feb;21(2):459-65. Epub 2005 Nov 1.

PMID:
16263739
15.
16.

Adherence to mineral and bone disorder clinical practice guidelines in chronic kidney disease.

Panawong W, Chaiyakum A, Pongskul C.

J Med Assoc Thai. 2011 Oct;94(10):1175-83.

PMID:
22145501
17.

Phosphate binder therapy for attainment of K/DOQI bone metabolism guidelines.

Nolan CR.

Kidney Int Suppl. 2005 Jul;(96):S7-14. Review.

PMID:
15954948
18.

Reappraisal of 2003 NKF-K/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients.

Monge M, Shahapuni I, Oprisiu R, El Esper N, Morinière P, Massy Z, Choukroun G, Fournier A.

Nat Clin Pract Nephrol. 2006 Jun;2(6):326-36.

PMID:
16932454
19.

Is 2.5 mEq/L the optimal calcium concentration of dialysate in the use of sevelamer hydrochloride? A study of the dialysate calcium concentration recommended by K/DOQI guidelines.

Izumi M, Shirai K, Ito K, Miyamoto T, Matsumoto A, Takenaka Y, Nakagawa K, Yamanashi T, Takamitsu Y, Nakanish T.

Ther Apher Dial. 2005 Feb;9(1):24-31.

PMID:
15828902
20.

Parathyroidectomy as a therapeutic tool for targeting the recommended NKF-K/DOQI ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients.

Mazzaferro S, Pasquali M, Farcomeni A, Vestri AR, Filippini A, Romani AM, Barresi G, Pugliese F.

Nephrol Dial Transplant. 2008 Jul;23(7):2319-23. doi: 10.1093/ndt/gfm931. Epub 2008 Feb 15.

PMID:
18281320

Supplemental Content

Support Center